APG Asset Management US Inc. Purchases 721 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

APG Asset Management US Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,953 shares of the company’s stock after acquiring an additional 721 shares during the quarter. APG Asset Management US Inc.’s holdings in Neurocrine Biosciences were worth $3,916,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in shares of Neurocrine Biosciences by 1.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 336,536 shares of the company’s stock valued at $44,343,000 after purchasing an additional 5,907 shares during the period. Janney Montgomery Scott LLC raised its stake in Neurocrine Biosciences by 87.5% in the fourth quarter. Janney Montgomery Scott LLC now owns 8,637 shares of the company’s stock valued at $1,138,000 after buying an additional 4,030 shares during the period. Norges Bank acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $35,731,000. UBS Group AG boosted its stake in shares of Neurocrine Biosciences by 6.4% during the 4th quarter. UBS Group AG now owns 143,894 shares of the company’s stock worth $18,959,000 after acquiring an additional 8,655 shares during the period. Finally, Hsbc Holdings PLC boosted its stake in shares of Neurocrine Biosciences by 33.3% during the 4th quarter. Hsbc Holdings PLC now owns 103,956 shares of the company’s stock worth $13,715,000 after acquiring an additional 25,975 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 1.2 %

Shares of NASDAQ:NBIX opened at $115.93 on Friday. The firm has a 50 day moving average of $136.67 and a 200-day moving average of $137.77. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98. The stock has a market capitalization of $11.67 billion, a PE ratio of 31.94 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.95 earnings per share. On average, research analysts predict that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 4th. JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. BMO Capital Markets lowered their price target on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating on the stock in a report on Thursday, August 29th. Finally, Morgan Stanley boosted their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $162.20.

Insider Transactions at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 7,143 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $150.10, for a total transaction of $1,072,164.30. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at $376,300.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William H. Rastetter sold 14,250 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,798 shares of company stock valued at $10,676,096. Corporate insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.